Association of KLOTHO polymorphisms with clinical complications of sickle cell anemia Jéssica V. G. F. BatistaDiego A. Pereira-MartinsMarcos A. Bezerra Original Article 14 June 2021 Pages: 1921 - 1927
Extracellular vesicles from thalassemia patients carry iron-containing ferritin and hemichrome that promote cardiac cell proliferation Anyapat AtipimonpatPanjaree SiwaponananKovit Pattanapanyasat Original Article 21 June 2021 Pages: 1929 - 1946
Priapism in patients with hemolytic disorders: a nationwide retrospective cohort study Stinne TranekærDennis Lund HansenHenrik Frederiksen Original Article 16 June 2021 Pages: 1947 - 1951
δ-Hemoglobinopathies in Thailand: screening, molecular basis, genotype-phenotype interaction, and implication for prevention and control of thalassemia Kritsada SinghaGoonnapa FucharoenSupan Fucharoen Original Article 08 April 2021 Pages: 1953 - 1963
Diagnosis and management of non-clonal erythrocytosis remains challenging: a single centre clinical experience Saša Anžej DomaEva DrnovšekIrena Preložnik Zupan Original Article Open access 19 May 2021 Pages: 1965 - 1973
The clinical significance of PNH-phenotype cells accounting for < 0.01% of total granulocytes detected by the Clinical and Laboratory Standards Institute methods in patients with bone marrow failure Kohei HosokawaKen IshiyamaShinji Nakao Original Article 23 October 2020 Pages: 1975 - 1982
Genetic alterations in Thai adult patients with acute myeloid leukemia and myelodysplastic syndrome—excess blasts detected by next-generation sequencing technique Weerapat OwattanapanichJulia HerzigKonstanze Döhner Original Article Open access 10 April 2021 Pages: 1983 - 1993
Clinical, biological, and prognostic implications of SF3B1 co-occurrence mutations in very low/low- and intermediate-risk MDS patients Kamila JanuszMarta Martín IzquierdoMaría Díez Campelo Original Article 06 January 2021 Pages: 1995 - 2004
Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib Giovanni CaocciOlga MulasGiorgio La Nasa Original Article 03 January 2021 Pages: 2005 - 2014
Direct oral anticoagulants (DOAC) for prevention of recurrent arterial or venous thromboembolic events (ATE/VTE) in myeloproliferative neoplasms Karlo HuenerbeinParvis SadjadianKai Wille Original Article Open access 20 November 2020 Pages: 2015 - 2022
Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1T315I and BCR-ABL1T315I-E255K Afsar Ali MianIsabella HaberboschJamal Mahajna Original Article Open access 10 June 2021 Pages: 2023 - 2029
Hematological characteristics, cytogenetic features, and post-induction measurable residual disease in thymic stromal lymphopoietin receptor (TSLPR) overexpressed B-cell acute lymphoblastic leukemia in an Indian cohort Harpreet VirkSonia RanaSreejesh Sreedharanunni Original Article 22 June 2021 Pages: 2031 - 2041
Reduction of immunosuppression combined with whole-brain radiotherapy and concurrent systemic rituximab is an effective yet toxic treatment of primary central nervous system post-transplant lymphoproliferative disorder (pCNS-PTLD): 14 cases from the prospective German PTLD registry Heiner ZimmermannMirko Nitschefor the German PTLD Study Group and German Lymphoma Alliance Original Article 11 May 2021 Pages: 2043 - 2050
Carfilzomib in addition to lenalidomide and dexamethasone in Asian patients with RRMM outside of a clinical trial Ji Hyun LeeYong Parkthe Korean multiple myeloma working party [KMMWP] Original Article 15 January 2021 Pages: 2051 - 2059
Low dose venetoclax in combination with bortezomib, daratumumab, and dexamethasone for the treatment of relapsed/refractory multiple myeloma patients—a single-center retrospective study Bernard RegidorMarissa-Skye GoldwaterJames R. Berenson Original Article 14 May 2021 Pages: 2061 - 2070
Pre-transplant donor-type red cell transfusion is a safe and effective strategy to reduce isohemagglutinin titers and prevent donor marrow infusion reactions in major ABO-mismatched transplants Pallavi MehtaStalin RamprakashLawrence Faulkner Original Article 19 June 2021 Pages: 2071 - 2078
Oral mucositis in patients with acute myeloid leukemia treated with allogeneic hematopoietic stem cell transplantation in relation to the conditioning used prior to transplantation Aleksandra Wysocka-SłowikLidia GilBarbara Dorocka-Bobkowska Original Article Open access 12 June 2021 Pages: 2079 - 2086
Letermovir prophylaxis is effective in preventing cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation: single-center real-world data Patrick DerigsAleksandar RadujkovicMichael Schmitt Original Article Open access 03 December 2020 Pages: 2087 - 2093
A prospective single-center study on CNI-free GVHD prophylaxis with everolimus plus mycophenolate mofetil in allogeneic HCT Henning SchäferJacqueline Blümel-LehmannReinhard Marks Original Article Open access 23 March 2021 Pages: 2095 - 2103
Eculizumab, a real-life successful treatment for refractory cold agglutinin–mediated auto-immune hemolytic anemia secondary to lymphoproliferative disorders Laura HerbreteauRonan Le CallochLenaïg Le Clech Letter to the Editor 18 May 2021 Pages: 2105 - 2106
Hemolytic erythrocytosis: an amalgamated phenotype from coinherited Chuvash polycythemia and G6PD Kerala-Kalyan with acquired transient stomatocytosis Manu JamwalNabhajit MallikReena Das Letter to the Editor 08 October 2020 Pages: 2107 - 2109
Acquired elliptocytosis as presenting sign of a myelodysplastic syndrome associated with deletion of chromosome 20 and mutations in TET2, DNMT3A, and U2AF1 Christoph RobierGerald HoeflerEva Hubmann Letter to the Editor 06 January 2021 Pages: 2111 - 2112
Paroxysmal nocturnal hemoglobinuria complicated with essential thrombocythemia harboring concomitant PIGA, CALR, and ASXL1 mutations Haruya OkamotoNobuhiko UoshimaJunya Kuroda Letter to the Editor 25 January 2021 Pages: 2113 - 2115
Management of myelofibrosis and concomitant advanced cutaneous squamous cell carcinoma with ruxolitinib associated with cemiplimab Alessio Di PrimaAndrea BotticelliMassimo Breccia Letter to the Editor 27 August 2020 Pages: 2117 - 2119
Faggot cells in acute myeloid leukemia with t(7;11)(p15;p15) and NUP98-HOXA9 fusion Hiroto YanagisawaShuichi MizutaYasufumi Masaki Letter to the Editor 08 June 2020 Pages: 2121 - 2123
Elevated plasma hemoglobin in COVID-19–related illnesses: a critical appraisal Nishant R. TiwariNagnath K. RedewadVivek R. Sharma Letter to the Editor 24 September 2020 Pages: 2125 - 2126
Plasma hemoglobin in COVID-19: authors’ reply Guido LancmanBridget K. MarcellinoKevin Troy Letter to the Editor 06 November 2020 Pages: 2127 - 2127
Management of chronic patients during the COVID-19 pandemic: the experience of a referral center for rare hematological disorders in the hardest-hit region in Italy Irene MottaAlessia MarconMarina Baldini Letter to the Editor 02 February 2021 Pages: 2129 - 2131
Blood and platelet transfusion from a donor with presymptomatic Covid-19 Konstantinos LiapisMenelaos PapoutselisIoannis Kotsianidis Letter to the Editor 13 November 2020 Pages: 2133 - 2134
Severe exacerbation of immune thrombocytopenia and COVID-19: the favorable response to corticosteroid-based therapy—a case report Zhiliang HuWei ChenYongxiang Yi Letter to the Editor 04 June 2020 Pages: 2135 - 2137
Thrombocytopenia in COVID-19: pathophysiology matters Eleni GavriilakiIoanna SakellariAchilles Anagnostopoulos Letter to the Editor 18 July 2020 Pages: 2139 - 2140
Correction to: Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents—a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group Esther SchulerEva-Maria Wagner-DrouetOn behalf of the German Cooperative Transplant Study Group Correction 23 June 2021 Pages: 2141 - 2142